AbbVie Competitive Strategy & Market Position
AbbVie's scale rests on its immunology portfolio, specialist commercial infrastructure, approved products across several therapeutic areas, and acquired oncology, neuroscience, and aesthetics assets. Those strengths are offset by patent-expiration, clinical-development, safety, reimbursement, and pricing risks described in its Form 10-K.
- What is AbbVie's competitive advantage?
- AbbVie's scale rests on its immunology portfolio, specialist commercial infrastructure, approved products across several therapeutic areas, and acquired oncology, neuroscience, and aesthetics assets.
- What is AbbVie's market share?
- AbbVie does not report company-wide market share. In FY2025 it reported $30.406 billion of immunology revenue, $10.767 billion of neuroscience revenue, $6.655 billion of oncology revenue, and $4.860 billion of aesthetics revenue.
Core Strength
Skyrizi generated $17.562 billion and Rinvoq generated $8.304 billion in FY2025 global net revenue, or $25.866 billion combined, after U.S. Humira biosimilar entry.
Key Weakness
Humira's decline shows the core weakness of the pharmaceutical model: even notable blockbusters eventually lose exclusivity. AbbVie must keep building new products before Skyrizi, Rinvoq, Botox, or other major assets face their own patent and pricing pressure.
Market Position & Competitive Landscape
AbbVie competes less like a diversified healthcare conglomerate and more like a focused specialty-drug operator. Johnson & Johnson and Pfizer have broader platforms, Eli Lilly has metabolic-drug momentum, and Amgen/Regeneron compete in biologics, but AbbVie remains especially strong in immunology and specialty commercial execution. The numbers show how far AbbVie has replaced Humira. It reported $61.160 billion of net revenue in FY2025 and $4.226 billion of net income. Skyrizi and Rinvoq generated $25.866 billion combined, while Humira declined to $4.540 billion after biosimilars entered the US market. It has bought its way into other areas: ImmunoGen added the cancer drug Elahere, Cerevel added neuroscience programs in clinical trials, and the 2020 Allergan acquisition added neuroscience and aesthetics revenue.
Key Competitors
| Competitor | Profile |
|---|---|
| Johnson And Johnson | View Profile → |
| Eli Lilly | View Profile → |
| Pfizer | View Profile → |
| Merck | View Profile → |
| Amgen | View Profile → |
| Bristol Myers Squibb | View Profile → |
AbbVie Competitors, SWOT and Strategy FAQ
Who are AbbVie's competitors?
AbbVie competes with global pharmaceutical companies including Johnson & Johnson, Eli Lilly, Pfizer, Merck, Amgen, Bristol Myers Squibb, Regeneron, Roche, Novartis, Sanofi, and AstraZeneca.
What supports AbbVie's immunology position?
Skyrizi and Rinvoq generated $25.866 billion combined in FY2025 across multiple approved immune-mediated disease indications.
How did the Allergan acquisition change AbbVie?
The acquisition added Botox, Juvederm, Vraylar, Ubrelvy, Qulipta, eye-care products, and Allergan Aesthetics.
What are AbbVie's principal competitive risks?
Its Form 10-K identifies patent loss, competing products, clinical-development risk, pricing pressure, and government action among its risks.
How is AbbVie defending its market share?
AbbVie aggressively transitions patients to its newer drugs, Skyrizi and Rinvoq, which boast superior efficacy profiles compared to older biosimilars.